Gliclazide is an oral hypoglycemic drug related to derivatives sulfonylureas 2nd generation. The action of the drug is aimed at activating β-cells in pancreasproducing insulin, increasing the susceptibility to it of peripheral tissues, strengthening insulin secretion effects of glucose and stimulation of intracellular activity glycogen synthetase in muscle tissue. The drug reduces the time period from the time of receipt of food to the beginning of production insulinreduces postprandial glucose leveland also restores the early (first) peak insulin secretion (unlike other drugs sulfonylureasmainly operating in the second phase).
In addition to adjusting carbohydrate metabolism gliclazide improves microcirculationby reducing platelet aggregation and adhesion, normalization of vascular permeability, recovery of the physiological process parietal fibrinolysis.
Glidiab therapy reduces vascular sensitivity to the effects of adrenaline rushprevents formation atherosclerosis and microthrombosis. Slows down the progression of nonproliferative (background) diabetic retinopathy. With prolonged treatment, a significant decrease is observed. proteinuriadeveloping on the backgrounddiabetic nephropathy.
Taking the drug, because of its effect on the early stage insulin secretion, is not accompanied by an increase in weight, and even favors its reduction in obese patients, if the corresponding diet therapy.
Oral intake gliclazide leads to its almost complete absorption in the digestive tract. Serum TCmax of blood makes 4 hours (for tablets MV - 6-12 hours). Plasma protein binding is between 90-95%. Metabolic changes occur in the liver with the release of inactive products. metabolism. T1 / 2 is 8-11 hours (for tablets MV - 16 hours). Derivation in the form metabolites is carried out mainly by the kidneys (about 70%), as well as the intestines (12%). Approximately 1% gliclazide excreted unchanged in the urine.
Indications for use
Application Glidiaba shown with treatment of type 2 diabetes (NIDDM, non-insulin dependent diabetes) with concurrent diet therapy and performingphysical exertion moderate complexity, in case of their inefficiency in the past.
Absolutely contraindicated intake Glidiaba with:
- diabetic ketoacidosis,
- type 1 diabetes,
- diabetic precoma /coma,
- severe liver pathologies/kidney,
- hyperosmolar coma,
- painful conditions, with the need to use insulinincluding injuries, surgeryextensive burns,
- paresis of the stomach,
- of pregnancy,
- intestinal obstruction,
- pathologies accompanied absorption disorders food and shaping hypoglycemia (including infectious diseases),
- personalized hypersensitivity to gliclazide or other components of drugs,
- in childhood.
The most common and serious side effect of Glidiab is hypoglycemiamost often arising from violations of the dosing regimen and inadequate diet therapy. The symptomatology of this complication is quite diverse and can occur: headachesfeeling of hunger feeling tireda sudden weaknessby carelessness anxiety, aggressivenessirritability depressive conditionsslow response, inability to concentrate, visual impairmenta sense of helplessness aphasia, sensory disorders, tremor, dizziness, delirium, loss of self control, crampsloss of consciousness hypersomniashallow breathing sweating, bradycardia.
Negative effects observed by the gastrointestinal tract, expressed in dyspepsia (nauseaepigastric and diarrhea), violations hepatic function (increased activityliver transaminase, cholestatic jaundice), anorexia (in the case of taking pills with food, the severity anorexia decreases).
May also develop allergic manifestationsmainly occurring urticaria, maculo-papular rash and pruritus.
Sometimes observed formation leukopenia, thrombocytopenia and anemia.
Glidiab, instructions for use
Selection of the dosage regimen of the drug Glidiab is carried out individually according to clinical manifestations. NIDDM and level glycemiawhich is measured on an empty stomach, as well as after 2 hours after a meal.
Initially, the daily intake of the 1st tablet of Glidiab 80 mg or the 1st tablet of Glidiab MB 30 mg is recommended. The average daily dosage is 160 mg and 60 mg, and the maximum is 320 mg and 120 mg, respectively, for tablets and MV tablets. Regular Glidiab tablets 80 mg taken 30-60 minutes before meals twice at 24 hours (morning and evening). CF tablets 30 mg is indicated to be taken once every morning at breakfast. Increasing doses can be carried out with an interval of at least 14 days.
Elderly patients and patients with kidney pathologies (with CC 15-80 ml / min) do not need to adjust the dose.
With an overdose gliclazide watched the development hypoglycemiasometimes reaching tohypoglycemic coma.
In the event that the symptoms of overdose allow the patient to be conscious, he should immediately drink. sugar solution or glucose (dextrose). In the unconscious state of the patient, it is shown in / in the introduction of the solution Dextrose (40%) or i / m injection Glucagon (1-2 mg). In the future, with some normalization of the condition, the patient should eat foods with a high content carbohydrateto prevent recurrence of hypoglycemia.
A decrease in the hypoglycemic efficacy of Glidiab is observed in the case of its parallel use with glucocorticoid, barbiturates, sympathomimetics (Terbutaline, Epinephrine, Ritodrin, Clonidine, Salbutamol), calcium antagonists, lithium salts, nicotinic acid, thiazide diuretics, carbonic anhydrase inhibitors (Diacarb), Chlorthalidone, Triamteren, Chlorpromazine, Furosemide, Asparaginase, Danazole, Baclofenom, Diazoxide, Rifampicin, Morphine, Isoniazid, Glucagon, Phenytoin, hormones thyroid and estrogen (including oral contraceptives).
An increase in the hypoglycemic activity of Glidiab is noted in its combined use with antifungal drugs (Fluconazole, Miconazole), ACE inhibitors (Enalapril, Captopril), H2-blockers (Cimetidine), fibrates (Bezafibrat, Clofibrate), NSAIDs (Indomethacin, Phenylbutazone, Diclofenac), salicylates, anti-tuberculosis drugs (Ethionamide), indirect anticoagulants, β-blockersanabolic steroids Cyclophosphamide, MAO inhibitors, Chloramphenicol, Teofillinom, Allopurinol, prolonged sulfonamides, Fenfluramine, Pentoxifylline, Fluoxetine, Guanethidine, Reserpine, blockers of tubular secretion, Disopyramide, Bromocriptine, Pyridoxine, ethanol, as well as with other hypoglycemic drugs (insulin, biguanides, acarbose).
Joint reception Glidiab and cardiac glycosides increases the risk of formation ventricular extrasystoles.
Effects of β-blockers, Reserpine, Clonidine, Guanethidine may hide clinical symptoms hypoglycemia.
Glidiab treatment should be supported bylow calorie diet therapywith minimal inclusion carbohydrate.
Deviations in the diet, as well as emotional and physical stress require dosage adjustment gliclazide.
Throughout the course of therapy, control must be exercised glycemiaby checking it on an empty stomach and after eating.
With decompensation diabetes, and surgical interventions possible assignment should be considered insulin containing drugs.
The patient should be informed about the possibility of forming hypoglycemia when fasting, taking NSAIDs and ethanol containing drugs.
Elderly patients, debilitated patients, or those who do not receive a balanced diet, as well as people suffering are especially sensitive to the effects of hypoglycemic drugs. hypocorticism.
Caution should be exercised when performing hazardous or precise work, as well as driving a car, especially during the selection of the dosing regimen, due to the increased risk of hypoglycemia.
- Eglim etc.
- Glidia MV,
- Diabeton mr,
- Gliclazide MR,
- Diagnostic MR,
The experience of treating Glidiab patients in the pediatric age group is not enough for its administration to children.
In the case of the reception of beverages containing alcohol during the passage of Glidiab therapy, the occurrence ofdisulfiram-like reaction (syndrome), manifested abdominal pain, nausea/vomit, headaches.
During pregnancy and lactation
Use in therapy of the drug Glidiab when breastfeeding and of pregnancy prohibited.
Encountered online reviews about Glydiab are few, but overwhelmingly positive. According to the patients taking it, the drug copes well with negative manifestations. insulin dependent diabetes and has a minimum of side effects. Naturally, when taking Gleediab should be maintained appropriate diet and follow the guidelines for physical stress.
Release form and composition
Dosage form of Glidiab MB - modified release tablets: flat-cylindrical, white with a creamy tinge or white, with a facet, marbling is acceptable (10 pieces each in blisters, in a cardboard box of 3 or 6 packs).
Ingredients 1 tablet:
- active ingredient: gliclazide - 30 mg,
- auxiliary components: microcrystalline cellulose - 123 mg, hypromellose - 44 mg, magnesium stearate - 2 mg, colloidal silicon dioxide - 1 mg.
After oral administration, gliclazide is almost completely absorbed from the gastrointestinal tract. Its plasma concentration increases gradually and reaches a maximum within 6–12 hours. Food intake has no effect on the absorption of a substance.
With daily intake of a single dose of Glidiab MB, an effective therapeutic plasma concentration of gliclazide is achieved for 24 hours.
Plasma protein binding is approximately 95%.
Metabolism occurs in the liver, followed by the formation of inactive metabolites.
T1/2 (half-life) is approximately 16 hours. Excreted mainly by the kidneys as metabolites, about 1% of the substance is excreted unchanged in the urine.
- type 1 diabetes,
- diabetic ketoacidosis,
- diabetic coma / precoma,
- conditions that are accompanied by a violation of food absorption, the occurrence of hypoglycemia (infectious diseases),
- hyperosmolar coma,
- paresis of the stomach,
- liver / kidney failure in severe course,
- intestinal obstruction
- extensive surgical interventions, extensive injuries, burns and other conditions that require insulin therapy,
- combination therapy with miconazole, danazol or phenylbutazone,
- age up to 18 years
- pregnancy and breastfeeding,
- individual intolerance to any of the components of the drug, as well as sulfonamides and other sulfonylurea derivatives.
Relative (Glidiab MB is prescribed under medical supervision):
- febrile syndrome
- unbalanced / irregular nutrition,
- pituitary / adrenal insufficiency,
- severe diseases of the cardiovascular system (including atherosclerosis, coronary heart disease),
- renal / hepatic failure,
- deficiency of glucose-6-phosphate dehydrogenase,
- prolonged use of glucocorticosteroids,
- thyroid disease, occurring in violation of its function,
- elderly age.
Instructions for use Glidiab MB: method and dosage
Glidiab MB taken orally, 1 time per day during breakfast.
The dose of the drug is selected by the doctor individually on the basis of the clinical manifestations of the disease, fasting glucose and 2 hours after meals.
Initial daily dose - 1 tablet. In the future, if necessary, increase the dose with an interval of at least 2 weeks. The maximum dose - 4 tablets per day.
It is possible to switch from Glidiab to Glidiab MB in a daily dose of 1-4 tablets.
Therapy can be combined with other hypoglycemic agents: biguanides, insulin or alpha-glucosidase inhibitors.
Combinations in which the blood glucose level may increase (weakening of the action of gliclazide):
- danazol: the combination is not recommended, the drug has a diabetogenic effect, when it is impossible to replace it with another drug, the blood glucose concentration should be monitored, during the combination therapy and after it is completed, the dose of Glidiaba MB can be adjusted by the doctor,
- chlorpromazine (daily dose of 100 mg): the combination requires caution, since there is an increase in the concentration of glucose in the blood and a decrease in insulin secretion; adjusted dose of Glidiab MB,
- tetrakozaktid and glucocorticosteroids (local / systemic use: intra-articular, rectal and external administration): the combination requires caution, since there is an increase in the concentration of glucose in the blood with the possible development of ketoacidosis, it is recommended to carefully monitor the concentration of glucose in the blood, especially at the beginning of therapy, during the combined therapy and after its completion by a doctor can be adjusted dose Glidiab MB,
- salbutamol, ritodrin, terbutaline (intravenous): the combination requires caution,
- anticoagulants (in particular, warfarin): increased effect of anticoagulants (may require correction of their dose).
Combinations in which the risk of hypoglycemia increases (increased action of gliclazide):
- miconazole (systemic or local application in the form of a gel on the mucous membranes of the oral cavity): the combination is contraindicated, since hypoglycemia can develop up to the state of coma,
- Phenylbutazone (systemic administration): the combination is not recommended, if it is not possible to replace it with another drug, the concentration of glucose in the blood should be monitored, the dose of Glidiab MB can be adjusted by the doctor during combination therapy and after its completion,
- ethanol: the combination is not recommended, which is associated with increased hypoglycemia and the likelihood of developing hypoglycemic coma,
- other hypoglycemic agents (insulin, alpha-glucosidase inhibitors, metformin, thiazolidinediones, apt-on of a kind of a nd-of-a-art;2- histamine receptors, monoamine oxidase inhibitors, clarithromycin, sulfonamides: the combination requires caution.
Analogues of Glidiab MB are: Diabeton MB, Diabefarm MV, Gliclazid Canon, Glidiab, Gliclada, Diabetalong, Diabinax, Diabefarm.
The medicine "Glidiab MV 30" is considered the Russian equivalent of the French drug "Diabeton MV". Produced by Akrikhin Chemical and Pharmaceutical Plant in the Moscow Region.
The drug refers to oral hypoglycemic agents in tablet form, having a modified release. The color of their structure is white or cream, there may be marble inclusions. Tablets resemble flat cylinders with a chamfer.
Consumer packaging is a pack. It may contain 30 or 60 tablets, packaged in blister plates.
In contrast to the medication “Diabeton MV” with a dose of 0.060 g of gliclazide, the drug “Glidiab MV” has an amount of the identical active ingredient two times lower, which is 0.030 g.
Inactive tablet components include hydroxypropyl methylcellulose, aerosilic molecules, magnesium stearate, microcrystalline cellulose.
There is also the drug "Glidiab" with the usual release of the active substance. The dosage in one tablet is 0.08 g of gliclazide.
Attached to the drug "Glidiab MB" instructions for use describes the effect of gliclazide, which stimulates insulin secretion in β-cells in the pancreas.
Under the influence of tablets, the insulin-secreting activity of glucose molecules increases, and peripheral tissues become more sensitive to the insulin hormone.
Muscle glycogen synthase, being an intracellular enzyme, is more effective. There is a decrease in the interval from the beginning of the use of food to the release of the hormone. Insulin secretion is restored at an early peak, which distinguishes gliclazide from the remaining sulfonylurea precursors, which are activated in the second stage. Postprandial glucose level decreases.
There is an improvement in microcirculation by combining and sticking platelet cells, normalizing the permeability of the vascular wall, reducing the development of microthrombosis and atherosclerosis processes, restoring the reactions of the natural dissolution of blood clots. The ability of receptor formations in the vessels to react to adrenaline molecules decreases.
The drug is able to slow down the diabetic nature of retinopathy at the non-proliferative stage. Long-term treatment with this agent in conditions of diabetic damage to the components of the renal parts responsible for filtration, can significantly reduce the excretion of proteins in the urine.
The drug does not increase the body mass, but rather reduces it due to the effect on the early stage of insulin secretion. It does not provoke increased insulinemia.
What is used
Doctors recommend using the drug for high blood sugar second degree. The treatment is carried out with insufficient effect from the diet and moderate physical exertion.
For the medication “Glidiab MB”, indications are associated with the prevention of deterioration in diabetic disorders characterized by nephropathy, retinopathy, myocardial infarction and stroke.
How to use
Dosing means is selected for each patient separately, taking into account the manifestations of the disease, the glucose concentration in an empty stomach and 120 minutes after eating the food.
For the Glidiab MB drug, the instructions for use prescribe a daily initial dose of 0.03 g, which is equivalent to one tablet. This concentration is indicated for elderly patients after 65 years of age. The drug is used orally in a single tablet in the morning when breakfast is served.
If necessary, the dosage is increased every two weeks. The maximum per day allowed to take about 0,120 g, which corresponds to 4 tablets.
The drug "Glidiab MB" is used instead of the drug of the same name with the usual release, consuming 1-4 tablets per day.
It is combined with a hypoglycemic agent based on biguanide, an alpha glucosidase inhibitor of insulin molecules.
When violations of the renal work of a weak or moderate nature, when the rate of creatinine excretion is not more than 0.080 liters per minute, the dosage is not reduced.
When you can not take
Tablets "Glidiab MB" instructions for use does not recommend the use of the first form of diabetes mellitus, with an increase in ketones in the urine, with gastric paresis, with hyperosmolar, diabetic coma and precoma, with large surgical operations and burn injuries, traumatic processes, when you need insulin treatment.
Contraindications are severe violations of hepatic or renal functioning, intestinal obstruction, changes in food absorption, the development of a hypoglycemic state.
You can not use the drug for fever, leukopenia, pregnancy, breastfeeding and excessive intolerance to the ingredients of the drug.
Care is required when administering the drug, special supervision and dosage selection for patients with alcohol dependence and thyroid disorders.
Features of treatment
For the drug "Glidiab MB" instructions for use indicates the need to combine it with a low-calorie diet food, including a low carbohydrate content. Requires regular monitoring of the concentration of glucose in the bloodstream in the morning before and after eating.
If there were surgical interventions or decompensation of the diabetic state, insulin may be administered.
There are warnings about the occurrence of the hypoglycemic process in the use of ethyl alcohol, non-steroidal anti-inflammatory substance and the lack of nutrition. Drinking alcohol can cause disulfiram-like syndrome, with head and stomach pain, nausea and vomiting.
It is necessary to adjust the dosage of the drug during physical or emotional stress and in case of untimely ingestion of food.
Especially sensitive to the effect of the remedies are the elderly, patients with unbalanced or poor nutrition, weakened patients who suffer from adrenal pituitary system failure.
At the initial pores of the drug in the selection of the dosage, if there is a predisposition to a hypoglycemic crisis, it is not necessary to perform actions that require increased attentiveness and a quick psychomotor reaction.
For the Glidiab MB tool, the instruction includes information on disorders in the endocrine organs in the event of a failure in the use of pills and in case of an unhealthy diet. Usually, a decrease in the level of glucose in the bloodstream causes the appearance of pain in the head, tired, hungry, helpless, anxious state of health, instant weakness, aggression, weak concentration, and depressive state. Also, there are changes in visual perception, tremor, sensory and convulsive disorder, dizziness, hypersomnia, shallow breathing, decrease in heart rate.
The digestive organs malfunction in the form of impaired absorption, nausea, diarrhea, anorexic appetite, functioning disorder of the liver cells, cholestatic jaundice, and an increase in the efficiency of transaminase enzymes.
Undesirable processes in the hematopoietic system are associated with a decrease in hemoglobin, the number of platelet and leukocyte cells.
The drug can cause allergic manifestations in the form of itching, urticaria, maculo-papular rash.
The instructions for use attached to the Glidiab MV product caution against overdosing, which is expressed by a decrease in the glucose concentration in the blood plasma. With a strong excess of the drug may develop a hypoglycemic coma.
To eliminate it, a person is given to eat some well absorbed hydrocarbons, for example, a piece of sugar. When a person is unconscious, a 40% dextrose or glucose solution is injected into a vein, and 1 mg glucagon is injected into the muscle. If the patient is awake, then he is forced to eat well-absorbed hydrocarbons to avoid a repeat of the hypoglycemic attack.
Combination with drugs
Hypoglycemic activity of the medication
The effect of tablets is increased with clofibrates and bezafibrates, anti-tuberculosis drugs from the group of ethionamide, salicylates, indirect anticoagulants of coumarin structure, anabolic steroids, cyclophosphamides, chloramphenicols, sulfanilamides with prolonged influence.
The drug is more effective in reducing blood plasma sugar, if you use blockers of tubular discharge, ethyl alcohol, acarbose, biguanide, insulin.
Reduced hypoglycemic effect tablets cause barbiturates, medicines based epinephrine, clonidine, terbutaline, ritodrine, salbutamol, even phenytoin, inhibitors of carbonic anhydrase enzyme type acetazolamide, thiazide diuretics, hormones of the thyroid gland, lithium-containing drugs, estrogen remedies.
Ethyl alcohol molecules can affect gliclazide with the onset of a disulfiram-like process.
The active component of the tablets causes untimely depolarization and contraction of the ventricles of the myocardial muscle when combined with cardiac glycosides.
Beta-adrenergic blocking agents, clonidine, reserpine, guanethidine drugs mask clinical hypoglycemia.
Opinions of patients
Important not only attached to the drug "Glidiab MB" instructions for use. Reviews tell us exactly what patients think about the effectiveness of the drug. This tool helps many patients to reduce the glucose concentration to normal values, and in combination with a diet changes the way of life of the patient.
People note that a positive feature of tablets is their convenient use in the morning. During the day you can not remember the need for treatment.
On the drug "Glidiab MB" reviews can be heard and of a negative nature associated with the ineffectiveness of this tool. Usually this happens with improper dosing, when a small amount of medication is prescribed.
Composition and forms of release
- Active: 0.03 g of gliclazide
- Auxiliary: hypromellose, MCC, Aerosil, E572.
The pills are in the form of a flat cylinder with beveled edges, white or creamy. Possible marbling of the structure is not a defect. Packed in 10 pieces in blisters. In cardboard packaging - 3 or 6 contour plates, instructions for use.
A drug with hypoglycemic action based on gliclazide, a derivative element of the second-generation sulfonylurea. Stimulates the production of insulin in the body, enhances the sensitivity of tissues to insulin and the insulin-secreting effect of glucose. Restores the normal peak of insulin secretion, improves microcirculation, reduces platelet aggregation, restores the necessary vascular permeability.
Taking the drug does not contribute to gaining extra pounds, since it mainly affects the formation of an early peak of insulin secretion.
Mode of application
The drug is designed exclusively for adult therapy. Tablets Glidiab MB in accordance with the instructions for use, taken once a day, it is best in the morning with food. Pills are ingested whole, they can not be cleared or crushed.
If for some reason the admission was missed, then it is not recommended to make up for the omission with a double dose. The forgotten pill must be drunk the next morning. The dosage of the drug, as well as any hypoglycemic drug, is always chosen individually for each patient in accordance with his blood glucose and hemoglobin readings.
The recommended initial dosage is 30 mg per day. Later it can be adjusted to 60, 90 and 120 mg. Increase the daily rate of drugs is allowed only a month after the first dose. The exceptions are cases when the initial treatment did not give the expected result, and the glucose level remained at the same level (before therapy). In this situation, the dosage can be increased earlier - after 14 days.
CH with maintenance treatment is 30-120 mg.
If it is necessary to transfer a patient from Glidiab 80 mg per pill with a prolonged action (MV 30 mg), it is carried out after checking the level of glucose in a 1: 1 ratio. If the patient has previously taken another hypoglycemic drug, then the translation should be done with the calculation of the CH of the previous drug and the time of its elimination. There is no need to comply with the transition period, the initial CH of Glidiab MB is 30 mg, after which it can be changed.
If the patient took tablets with a long period of excretion of the active ingredient, it is necessary to take a break in order to prevent an additive effect. After that, you can start taking a prolonged drug in compliance with a daily dosage of 30 mg.
Dosage adjustment by age for elderly patients (65+) is not required. For persons at risk is assigned CH 30 mg.
When preventing complications of diabetes, the daily dosage can be increased to a maximum value of 120 mg as an additional measure to diet and physical activity. Reception is carried out before normalization of indicators, taking into account the risk of hypoglycemia.
During pregnancy, HB
Oral drugs that reduce glucose in the blood, the use of women in the period of carrying a child is highly undesirable, since there is no evidence of the safety of Glidiab MV.
When preparing for pregnancy or when it occurs on the background of the course of Glidiab MB tablets, the drug should be canceled and the woman should be given insulin therapy.
There is no reliable data whether the active ingredient penetrates into breast milk, therefore it is highly undesirable to combine hypoglycemic drugs with lactation. At the time of taking the HB tablets should be canceled, so as not to provoke a decrease in blood glucose level in the child.
During treatment with Glidiab MB tablets, it is necessary to take into account the ability of gliclazide to react with substances of other drugs.Especially dangerous may be the combination with drugs that enhance the effect of gliclazide, as the threat of hypoglycemic coma increases dramatically.
It is strictly forbidden to combine therapy with Glidiab MB with Miconazole (systemic or externally in the form of a gel), as this contributes to a severe form of coma, which can be fatal.
It is not recommended to combine the drug with phenylbutazone for the same reason. It should be replaced with another anti-inflammatory drug. If it is impossible, the patient should be aware of the possible risks and the need for constant monitoring of blood glucose.
It is forbidden to combine with ethanol-containing drinks or drugs, since alcohol contributes to the development of hypoglycemic coma.
There are a number of drugs that can be prescribed with caution along with Glidiab MB. Such remedies include insulin, metformin, alpha-glucoside inhibitors, beta-blockers, sulfonamides, NSAIDs, etc. If you need to use them, you should carefully monitor unwanted symptoms.
Danazol has a diabetogenic effect, weakens the effect of glycidal and increases the concentration of glucose in the blood. If it is not possible to replace the drug with another drug, the patient must constantly monitor the level of sugar, if necessary, the dosage adjustment of Glidiab MV is carried out.
Chlorpromazine helps to increase blood glucose levels and reduce insulin synthesis. Constant monitoring of sugar in diabetics is necessary, careful determination of the dosage of gliclazide when Glidiab MB is used together during treatment with Chlorpromazine and after its withdrawal.
Drugs with corticosteroids with any method of application (external, local, / s or rectal) increase the glucose concentration and contribute to the occurrence of ketoacidosis. When combined with this type of drug, regular monitoring of sugar in the blood is carried out and it is necessary to carefully determine the safest dosage both during the simultaneous course and after hormone therapy.
With a joint course with anticoagulants, it is possible to enhance their action. Dose adjustment required.
Taking tablets Glidiab MB may be accompanied by undesirable reactions of the body.
Like all drugs of the sulfonylurea group, the medication can provoke hypoglycemia if the pills are taken irregularly and especially often with missed meals. In such cases, the condition is accompanied by:
- Head aches
- Very strong hunger
- Nausea, bouts of vomiting
- Insomnia or sleepiness
- Severe irritability
- Nervous excitement
- Inhibited reactions
- Disorder of consciousness, speech and vision
- Shallow breathing
- In severe cases, loss of consciousness is possible, followed by coma or death.
Also, the patient may experience other reactions:
- Skin stickiness
- Increased blood pressure
- Angina pectoris
In other cases, the pill may be accompanied by various disorders of certain organs:
- Gastrointestinal: nausea, bouts of vomiting, abdominal pain, diarrhea or constipation. To avoid undesirable states or reduce their intensity, tablets are recommended to be taken with food.
- Skin: rash, itching, angioedema, erythema, bullous reactions.
- Blood formation organs: anemia, leukopenia, thrombocytopenia. The conditions are temporary: they pass on their own after the drug is canceled.
- Liver: activation of enzymes, in rare cases - hepatitis. If signs of cholestatic jaundice appear, then therapy should be canceled.
- Vision organs: decrease in visual acuity (most often occurs at the beginning of the course due to changes in glucose content).
Other side effects typical of sulfonylurea drugs include:
Terms and conditions of storage
Glidiab is a prescription drug.
Tablets should be stored in a dry place inaccessible to moisture penetration and exposure to sunlight, at temperatures up to 25 ºС. If these conditions are met, Glidiab’s shelf life is 4 years, and Glidiab MB is 2 years.
Found a mistake in the text? Select it and press Ctrl + Enter.
The principle of the drug
The drug for the treatment of "sweet" disease of the second type is available in tablet form, the main active ingredient of the drug is gliclazide. The composition of the tablets includes additional components - microcrystalline cellulose, magnesium stearate and other substances.
The abbreviation "MV", available in the name of the drug, is interpreted as a modified release. Reviews of doctors claim that this nuance allows you to take the tool once a day.
The main substance during absorption helps to stimulate the activity of muscle glycogen synthetase and the production of the hormone insulin in the body. In addition, the main component causes the insulin-secreting action of sugar, resulting in increased sensitivity to it at the cellular level.
It is also important that the tablets Glidiab help reduce the interval between the use of food and the beginning of the active production of insulin. Annotation to the tool suggests that the use of the drug lowers the peak of the hyperglycemic state, while there is a recovery of the early peak of hormone production.
All the above factors have a direct impact on the metabolism of carbohydrates and microcirculation. The use of the drug Glidiab reduces the likelihood of atherosclerotic changes in blood vessels.
Due to the peculiarities of the dosage form, a single dose per day ensures the effective therapeutic concentration of the active substance in the plasma for 24 hours.
Instructions for use tablets
Abstract drug Glidiab MB indicates that the drug is recommended for the treatment of diabetes in combination with a low carbohydrate diet and optimal physical activity.
As a rule, medication always acts as the only means to reduce blood sugar. Only in exceptional cases can be recommended in the complex therapy of the disease. For example, in combination with drugs from the biguanide group.
The dosage of the drug is prescribed based on the indicators of the sugar content on an empty stomach, as well as two hours after a meal.
On Glídiab, instructions for use provide the following information:
- Tablets are recommended to be taken once a day, the optimal time is the morning before meals.
- On average, the dosage per day is 80 mg, including for patients in the elderly age group (over 65).
- With insufficient therapeutic effect, it is permissible to gradually increase the dosage with an interval of 14 days.
- The maximum dosage per day is not more than 320 mg.
If the patient has impaired liver and kidney function, then dose adjustment of the drug Glidiab MB is not required.
The price of the medicine, where the volume of the substance is 80 mg (60 tablets per pack) is 134 rubles. The price of 60 tablets in a dosage of 30 mg - 130 rubles. Glidiab MB is slightly more expensive, the price for 60 pcs. 80 mg is 185 rubles.
Analogs of the drug
In some situations, Glidiab is not appropriate to prescribe due to the presence of contraindications, a high probability of complications from the central nervous system and the cardiovascular system.
In this case, similar drugs are recommended. On Glidiab analogs are the following: Formetin, Amaril, Diabrex, Maninil, Glurenorm and other drugs for the treatment of diabetes.
The replacement of the drug with one or another medicine should be carried out exclusively by the attending physician, nothing else.
Consider analogues in more detail:
- Formetin is a drug recommended for the treatment of type 2 diabetes when diet therapy has not been fully effective. It is often recommended in combination with drugs that are derived from sulfonylureas.
- Maninil tablets have the main active ingredient glibenclamide, are derived from sulfonylureas. The drug promotes the active production of insulin, provides insulin secretion of glucose.
- Glibenclamide is prescribed for the second type of diabetes, when it is not possible to achieve compensation for pathology through diet and sports. The dosage is prescribed based on the performance of sugar, can vary from 2.5 to 15 mg. Frequency of use several times a day.
- Amaryl, a hypoglycemic agent, is prescribed to treat the second type of ailment as a single drug or in combination with insulin or metformin. As a rule, treatment with this drug is carried out for a long time.
The drug Glidiab and its analogues are highly effective in the treatment of "sweet" disease. However, along with the positive property, they have contraindications and side effects. Therefore, the appointment should be done only by a doctor.
Taking pills helps the body reduce glucose levels and stabilize them at the required level. But, in order to enhance the effectiveness of the use of drugs, the patient must follow a diet and play sports to increase the susceptibility of soft tissues to glucose.
What do you think about this? What drug is prescribed by your doctor, and what can you tell about him from the perspective of your own experience?